The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab) on September 17, 2019. This approval, designated as supplemental application BLA 125514 S-65, expands the drug's efficacy indication based on new clinical data reviewed by the agency.
Background
Pembrolizumab, marketed as Keytruda by Merck Sharp & Dohme, is an established immunotherapy used in the treatment of various cancers. This supplemental approval signifies an expansion of its therapeutic scope, building upon its existing approvals for different indications and patient populations.
What this means
This supplemental FDA approval for Keytruda (pembrolizumab) indicates that the drug's approved indications have been expanded based on new efficacy data submitted by the sponsor. For healthcare professionals, this means pembrolizumab is now approved for an additional patient population or a new disease state, providing a new treatment option where it may not have been previously indicated. This expansion reflects the ongoing clinical development and evaluation of pembrolizumab to address unmet medical needs in oncology.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for Keytruda (pembrolizumab) was documented as a supplemental application (BLA 125514 S-65) on September 17, 2019, and is publicly accessible via the accessdata.fda.gov website, which hosts official FDA drug approval documents.